Navigation Links
Human Genome Sciences to Sponsor Conference Call
Date:12/8/2008

ROCKVILLE, Md., Dec. 8 /PRNewswire-FirstCall/ --Human Genome Sciences, Inc. (Nasdaq: HGSI) today announced that it will sponsor a conference call to discuss the results of ACHIEVE 2/3, its Phase 3 trial of Albuferon(R) (albinterferon alfa-2b) in chronic hepatitis C.

(Logo: http://www.newscom.com/cgi-bin/prnh/20080416/HGSLOGO )

The conference call will be hosted by senior management and will be held on Monday, December 8, 2008 at 8:15 am Eastern Time.

Investors may listen to the call by dialing 888-215-6982 or 913-312-0389, passcode 7154642, five to 10 minutes before the start of the call. A replay of the conference call will be available within a few hours after the call ends. Investors may listen to the replay by dialing (888) 203-1112 or (719) 457-0820, confirmation code 7154642.

This conference call also will be webcast and may be accessed at www.hgsi.com. Investors interested in listening to the live webcast should log on before the conference call begins in order to download any software required. The archive of the conference call will remain available for several days.

The mission of HGS is to apply great science and great medicine to bring innovative drugs to patients with unmet medical needs.

HGS and Human Genome Sciences are trademarks of Human Genome Sciences, Inc.

SafeHarbor Statement

This announcement contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. The forward-looking statements are based on Human Genome Sciences' current intent, belief and expectations. These statements are not guarantees of future performance and are subject to certain risks and uncertainties that are difficult to predict. Actual results may differ materially from these forward-looking statements because of the Company's unproven business model, its dependence on new technologies, the uncertainty and timing of clinical trials, the Company's ability to develop and commercialize products, its dependence on collaborators for services and revenue, its substantial indebtedness and lease obligations, its changing requirements and costs associated with planned facilities and clinical trials, intense competition, the uncertainty of patent and intellectual property protection, the Company's dependence on key management and key suppliers, the uncertainty of regulation of products, the impact of future alliances or transactions and other risks described in the Company's filings with the Securities and Exchange Commission. In addition, the Company will continue to face risks related to animal and human testing, to the manufacture of ABthrax and to FDA concurrence that ABthrax meets the requirements of the ABthrax contract. If the Company is unable to meet the product requirements associated with the ABthrax contract, the U.S. Government will not be required to reimburse the Company for the costs incurred or to purchase any ABthrax doses. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of today's date. Human Genome Sciences undertakes no obligation to update or revise the information contained in this announcement whether as a result of new information, future events or circumstances or otherwise.


'/>"/>
SOURCE Human Genome Sciences, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Community Unites for Physicians for Human Rights Town Meeting on Global AIDS and Human Rights on December 8
2. CA$2.4 million toward gene therapy for human degenerative retinal diseases
3. NHS Human Services to Take Over Tri County Human Services Center
4. Saint Barnabas Medical Center Pioneers New Program Bringing Humanities and Humanism to Medicine
5. European Committee for Human Medicinal Products (CHMP) Issues Positive Opinion for Once-Daily PREZISTA(R) (Darunavir) as Part of Combination Therapy for Treatment-Naive Adults With HIV-1
6. MINRAD International, Inc. Announces Termination of RxElite Holdings Inc. as Anesthetics Distributor for the Human Market in United States
7. Public health and human rights: The work ahead of us
8. NCPA Statement on Tom Daschle Being Selected to Be Secretary of Health and Human Services Department
9. Bloomberg School awards Goodermote Humanitarian Award to Soledad OBrien
10. Bound by attention: Bringing rats and humans together
11. Antibiotics can cause pervasive, persistant changes to microbiota in human gut
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/23/2017)... ... ... 150+ Hospital and Health System Executive Speakers including: , , Chief ... the United States of America: George W. Bush , Boxing Legend, Successful Entrepreneur ... Leonard , JD, Chairperson, McGuireWoods LLP: Amber McGraw Walsh , Senior ...
(Date:3/23/2017)... Grants Pass, OR (PRWEB) , ... March 23, 2017 , ... ... Power of Water, Global Climate Change and Your Health on VoiceAmerica, recently talked on ... 22nd, but she also used the occasion to remind listeners of an important distinction. ...
(Date:3/23/2017)... ... March 23, 2017 , ... Natural ... all aspects of people’s health and nutrition, announced its product Leyzene is now ... Natural Subsistence develops nutritional supplements that help people improve all aspects of their ...
(Date:3/23/2017)... ... ... Inflow IQ & Inflownomics of Raleigh, NC introduce a powerful information access network. ... experts in dangerous situations the Inflow IQ team can help people. Get ready ... & refreshing knowledge systems that enhance life. , Authentically enjoy 500 ...
(Date:3/23/2017)... ... , ... The American Board of Quality Assurance and Utilization Review Physicians (ABQAURP) ... Health Care Quality and Management and Patient Safety. , It is with appreciation and ... also to the Health Care Quality and Patient Safety movements. Diplomates and Members lead ...
Breaking Medicine News(10 mins):
(Date:3/23/2017)... 23, 2017  Additive Orthopaedics, LLC., an early ... has kicked off a multi-centered clinical study to ... segments. According to Brian McLaughlin ... lattice structures have already shown tremendous post-operative success ... allograft wedges from which we have seen evidence ...
(Date:3/23/2017)... 23, 2017 Newborns are highly vulnerable ... vaccines because their young immune systems typically mount ... Hospital report achieving strong vaccine responses in newborn ... before human trials — by adding compounds known ... two simultaneous papers, they also describe improved adjuvant ...
(Date:3/23/2017)...  A new genetic test has been discovered ... who carry HLA-B*15:02 and who are ... deadly side effect of certain medications used to ... HLA-B*15:02 is strongly associated with life-threatening severe ... toxic epidermal necrolysis in patients treated with carbamazepine ...
Breaking Medicine Technology: